_utilizing-common-viruses-to-combat-dangerous-cancers-hear-from-the-leaders-at-theriva-therapeutics.jpg "Utilizing Common Viruses To Combat Dangerous Cancers - Hear From The Leaders At Theriva Therapeutics from oscine therapeutics Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 14:46
👁 View: 7.9M times
✓ Published: 26-Mar-2024
👁 View: 7.9M times
✓ Published: 26-Mar-2024
Description:
Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy.<br/><br/>The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and enhance the effects of current standard-of-care therapies. Engineered for systemic delivery, Theriva’s oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment (intratumoral, intravitreal).
Theriva is developing highly differentiated oncolytic adenoviruses that are designed to overcome the challenges of accessibility, availability, and administration and can potentially enable multiple dosing to improve efficacy.<br/><br/>The unique therapeutic properties of Theriva’s oncolytic viruses represent a new class of cancer treatments that are designed to selectively destroy tumor cells and enhance the effects of current standard-of-care therapies. Engineered for systemic delivery, Theriva’s oncolytic viruses can be administered intravenously or as a direct injection into the tumor or tumor compartment (intratumoral, intravitreal).
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_crispr-therapeutics-ceo-science-in-gene-editing-is-moving-at-break-neck-speed.webp "CNBC Television")
⏲ 3 minutes 39 seconds 👁 9.7K
_cell-therapies-amp-the-future-of-biotech-124.webp "SALT")
_the-ceo-of-this-innovative-biopharma-is-bringing-light-to-cancer-research.webp "Paul Peter Tak, MD, PhD, FMedSci, President & CEO of Candel Therapeutics, was recently a guest on Benzinga's All-Acess.<br/><br/>Candel is a clinical-stage biopharmaceutical company focused on developing immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The company has two main platforms that are currently undergoing clinical trials. <br/><br/>Candel also has its enLIGHTEN™ program, a systematic, iterative discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.")
_episode-3-how-to-start-your-own-biotech-company-part-1-therapeutics.webp "NCI Scientific Events and Resources")
_crispr-therapeutics-ceo-science-in-gene-editing-is-moving-at-break-neck-speed.jpg)
_cell-therapies-amp-the-future-of-biotech-124.jpg)
_the-ceo-of-this-innovative-biopharma-is-bringing-light-to-cancer-research.jpg)
_episode-3-how-to-start-your-own-biotech-company-part-1-therapeutics.jpg)
![[+]](/images/menu.gif){kind=small}